查詢結果分析
來源資料
相關文獻
- The Effects of Ursodeoxycholic Acid in Patients with Severe Obstructive Jaundice after Drainage Procedure
- The Role of Endoscopic Ultrasound in the Diagnosis of Obstructive Jaundice
- 阻塞性黃疸
- Effects of S-Adenosyl-L-Methionine on Liver Damage in Experimental Obstructive Jaundice
- 經皮穿肝膽管造影術及經皮穿肝膽汁引流術
- 阻塞性黃疸病人吞服大量Glibenclamide自殺--一病例報告
- Changes of Insulin and Somatostatin and Their Relationship to Liver Regeneration in Experimental Obstructive Jaundice
- Three-Dimensional magnetic Resonance Cholangiopancreatography for Evaluation of Obstructive Jaundice
- Icteric Type Hepatocellular Carcinoma: Clinical Features, Diagnosis and Treatment
- Obstructive Jaundice Caused by Absence of Common Bile Duct: A Case Report
頁籤選單縮合
題 名 | The Effects of Ursodeoxycholic Acid in Patients with Severe Obstructive Jaundice after Drainage Procedure=Ursodeoxycholic Acid對嚴重阻塞性黃疸病人引流後之治療效果 |
---|---|
作 者 | 許春暉; 盧俊良; 陳祖裕; 林素華; 張扶陽; 李壽東; | 書刊名 | 中華醫學雜誌 |
卷 期 | 60:3 1997.09[民86.09] |
頁 次 | 頁142-146 |
分類號 | 416.247 |
關鍵詞 | 膽汁引流; 阻塞性黃疸; Biliary drainage; Obstructive jaundice; Ursodeoxycholic acid; |
語 文 | 英文(English) |
中文摘要 | 背景:本研究之主要目的是要評估ursodeoxycholic acid(UDCA)對已接受引流之嚴重阻塞性黃疸病人是否有治療之角色。 方法:自1993年9月至1994年12月期間,因嚴重阻塞性黃疸(血清總膽紅素值高於15mg/dL 者)接受引流術的患者列入為研究對象。他們被隨機分為兩組,UDCA 組每日給予UDCA 600 毫克,安慰組予外貌相同之安慰劑,服藥時間始於引流後當天至病人接受手術、出院或死亡為止。此外,每日記錄膽汁流量、臨床症狀或徵候及藥物副作用。肝生化學試驗項目包括血清白蛋白、總膽紅素、膽固醇、氨基丙酸氨基轉移�t、天門冬酸氨基轉移�t、鹼性磷酸�t、伽馬麩氨酸轉胜�t及凝血�t原時間,於引流前及引流後第三天、第七天及以後每週檢查。 結果:共有38位病人完成研究過程(其中男性36位、女性2位,平均年鹼66.6 ± 6.4歲),其中18位為UDCA組,20位為安慰組。兩組間之年鹼、性別、阻塞性黃疸原因及接受引流方式並無差異。兩組病人之肝生化學試驗於引流後有明顯改善;然而,兩組間之膽汁引流量及肝生化學試驗改善程度,尤其是膽紅素之下降率並無明顯差異。 結論:本研究顯示嚴重阻塞性黃疸病人在引流成功後,服用UDCA並不能加速黃疸下降或其他肝生化學之改善。 |
英文摘要 | Background: The aim of this study is to evaluate the therapeutic effect of ursodeoxycholic acid (UDCA) for patients with severe obstructive jaundice after drainage procedure. Method: From September 1993 to December 1994, patients admitted with severe obstructive jaundice (serum bilirubin>15 mg/dl) and successful drainage were enrolled into our study. They were randomly divided into two groups to receive UDCA 600mg per day (UDCA group) or a placebo (placebo group) until operation or discharge. Bile drainage amount, clinical symptoms and signs and adverse effects of drugs were recorded daily. Biochemical tests, including albumin, total bilirubin, cholesterol, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, γ-glutamyl transpeptidase and prothrombin time, were checked first, on the third and seventh days, and then two weeks after drainage. Results: Thirty-eight patients (M/F=36/2, mean age 66.6±6.4 years) completed the study, 18 in the UDCA group and 20 in the placebo group. There were no differences in age, sex, causes of obstructive jaundice or methods of drainage procedure between the UDCA and placebo groups. Improvement in biochemical test results were noted in both groups. However, bile drainage amount and changes in liver biochemical test, especially the decrement of serum bilirubin, were not significantly different between both groups. Conclusions: UDCA seemed not to benefit patients with severe obstructive jaundice after successful drainage. |
本系統中英文摘要資訊取自各篇刊載內容。